|
Rheumatoid Arthritis
|
0.230 |
Biomarker
|
disease |
MGD |
|
|
|
|
Kidney Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
DNase II polymorphisms associated with risk of renal disorder among systemic lupus erythematosus patients.
|
15723160 |
2005 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
DNase II(-/-) embryos suffer from lethal anemia due to IFN-beta produced in the macrophages carrying undigested DNA.
|
20706988 |
2010 |
|
Hypothyroidism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Based on these results, we can conclude that in the liver of hypothyroid rats the transcriptional activation by T2 of DNL genes could depend, at least in part, on SREBP-1- and ChREBP-dependent mechanisms.© 2019 IUBMB Life, 2019.
|
30707786 |
2019 |
|
Arthritis, Adjuvant-Induced
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Splenomegaly
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Arthritis, Collagen-Induced
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Arthritis, Experimental
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Fibrosis, Liver
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Dnase2<sup>-/-</sup> Ifnar<sup>-/-</sup> mice were shown to recapitulate many features of the DNase II-deficient patients including cytopenia, extramedullary hematopoiesis and liver fibrosis.
|
31464028 |
2020 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Genetic associations of DNase II with SLE and related phenotypes were examined in Korean patients with SLE.
|
15723160 |
2005 |
|
Fatty Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we give an overview of the mechanisms of THs action on liver fatty acid metabolism, focusing on the different effects exerted by T2 and T3 on the regulation of the DNL.
|
28362337 |
2017 |
|
Liver carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
However, the effects of SNPs in DNL genes on overall survival of HCC patients receiving transarterial chemoembolization (TACE) treatment are still unknown.
|
25735330 |
2015 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
In addition, if nucleases, such as DNase II or DNase III (Trex1), fail to clear self-DNA, accumulated DNA gains access to intracellular compartments where it drives inflammatory responses leading to autoimmune disease.
|
23417527 |
2013 |
|
Fibrosis, Liver
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In fatty livers, DNase II activity is suppressed in contrast to simple inactivation of Bcl-xL or Mcl-1, and both apoptotic and non-apoptotic hepatocyte death can develop, leading to the progression of liver fibrosis.
|
29855540 |
2019 |
|
Autoimmune disease (systemic) NOS
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inefficient and abnormal clearance of apoptotic cells (efferocytosis) contributes to systemic autoimmune disease in humans and mice, and inefficient chromosomal DNA degradation by DNAse II leads to systemic polyarthritis and a cytokine storm.
|
29118755 |
2017 |
|
Polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inefficient and abnormal clearance of apoptotic cells (efferocytosis) contributes to systemic autoimmune disease in humans and mice, and inefficient chromosomal DNA degradation by DNAse II leads to systemic polyarthritis and a cytokine storm.
|
29118755 |
2017 |
|
Cytokine storm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inefficient and abnormal clearance of apoptotic cells (efferocytosis) contributes to systemic autoimmune disease in humans and mice, and inefficient chromosomal DNA degradation by DNAse II leads to systemic polyarthritis and a cytokine storm.
|
29118755 |
2017 |
|
Fatty Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inhibition of DNL is a successful approach to reverse hepatic steatosis, as shown by different studies in mice and humans.
|
30630736 |
2019 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of DNL is a successful approach to reverse hepatic steatosis, as shown by different studies in mice and humans.
|
30630736 |
2019 |
|
Rheumatoid Arthritis
|
0.230 |
GeneticVariation
|
disease |
BEFREE |
Intriguingly, homozygosity for the RA associated DNASE2 -1066 G allele had an additive effect on the disease susceptibility conferred by the wt allele of CCR5 (OR = 2.24, P = 0.0051 for carrier of both RA associated alleles)
|
19538721 |
2009 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Most Dnase1 and Dnase2 family members are poorly characterized, yet their elimination can lead to a wide range of diseases, including lethal anemia, parakeratosis, cataracts and systemic lupus erythematosus.
|
28666955 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Most Dnase1 and Dnase2 family members are poorly characterized, yet their elimination can lead to a wide range of diseases, including lethal anemia, parakeratosis, cataracts and systemic lupus erythematosus.
|
28666955 |
2017 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium.
|
19862010 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the SNPs in DNL genes may serve as independent prognostic markers for NSCLC patients after surgery.
|
25227797 |
2014 |
|
Autoinflammatory disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Patients with hypomorphic mutations in DNase II develop a severe and debilitating autoinflammatory disease.
|
31464028 |
2020 |